A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Zirconium silicate (Primary) ; Glucose; Insulin
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms ENERGIZE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Nov 2017 Planned End Date changed from 9 Jul 2018 to 5 Jul 2018.
    • 16 Nov 2017 Planned primary completion date changed from 9 Jul 2018 to 5 Jul 2018.
    • 16 Nov 2017 Planned initiation date changed from 24 Jan 2018 to 22 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top